anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Previous studies demonstrated that wedge resection is sufficient for ground glass-dominant lung adenocarcinoma (LUAD) with tumour diameter ≤2 cm, however, the optimal surgical type for ground glass-dominant LUAD with tumour diameter of 2-3 cm remains unclear. The purpose of this trial is to investigate the safety and efficacy of segmentectomy for ground glass-dominant invasive LUAD with tumour size of 2-3 cm.
METHODS AND ANALYSIS: We initiated a phase III trial to investigate whether segmentectomy is suitable for ground glass-dominant invasive LUAD with tumour size of 2-3 cm. This trial plans to enrol 307 patients from multiple institutions including four general hospitals and two specialty cancer hospitals over a period of 5 years. The primary endpoint is 5 year disease-free survival. Secondary endpoints are lung function, 5 year overall survival, the site of tumour recurrence and metastasis, segmentectomy completion rate, radical segmentectomy (R0 resection) completion rate and surgery-related complications.
ETHICS AND DISSEMINATION: This trial has been approved by the Ethics Committee of Fudan University Shanghai Cancer Centre (reference 2212267-18) and by the institutional review boards of each participating centre. Written informed consent is required from all participants. The study results will be published in a peer-reviewed international journal.
TRIAL REGISTRATION NUMBER: NCT05717803.
FIELD: medicine, rheumatology. SUBSTANCE: method involves administration of nonsteroid anti-inflammatory agents and ceruloplasmin. Ceruloplasmin is administrated by intravenous route by drops, 10 times each other day. Before administration 100 mg of ceruloplasmin is dissolved in 200 ml of 5% glucose or physiological solution. Method ensures to correct serum enzymatic link of antioxidant system and decrease the endogenic intoxication in this pathology. EFFECT: enhanced effectiveness of treatment. 2 cl, 2 ex
The invention relates to a method for isolating multipotent stem cells from dental tissue, according to which the stem cells are obtained from a tissue composite and are subsequently cultivated. The invention also relates to stem cells that have been isolated using said method and to osteocytes and neuronal cells, which have been obtained by means of said method. The invention further relates to a method for producing a bank of stem cells, according to which the cells thus obtained are stored. According to the invention, the cells of cushion-type soft tissue, which can be localised beneath the papilla on the apical side of an extracted immature tooth, are cryopreserved in a tissue composite. The tissue composite is only broken down to obtain the stem cells after being defrosted. The results indicate that stem or progenitor cells can be isolated even after the cryopreservation of the original tissue and that said stem or progenitor cells react to osteogenic stimulation. In addition, the cells react to a greater extent after cryopreservation than without the latter.
OSA is a chronic disorder characterized by frequent reduction and/or cessation of inspiratory airflow during sleep, with resulting hypoxemia and hypercapnia that are terminated by arousals. This pattern of repetitive arousals and nocturnal hypoxemia leads to disruption of sleep architecture and daytime hyper-somnolence as well as a multitude of neurobehavioral and cardiopulmonary derangements. All patients diagnosed with OSA should be instructed to undergo behavioral changes such as weight loss, avoidance of alcohol and sedatives, sleeping on the side and improvement in sleep hygiene, such as keeping a regular sleep schedule and getting an adequate amount of sleep. Continuous Positive Airways Pressure (CPAP) is currently considered to be the cornerstone of therapy for sleep apnea (OSA). However compliance with this treatment is frequently poor, which may lead to ongoing symptoms of sleep disruption, daytime sleepiness and poor waking cognitive function. Mechanical and psychological/educational interventions have been proposed to try to increase the hours of use of CPAP therapy. In older male patients with OSA, compliance with CPAP therapy is associated with attendance at a patient CPAP education and support group. Resolution of symptoms with therapy also appears to be associated with enhanced compliance. Some studies suggest that there is no direct causal relationship between OSA and gastro esophageal reflux disease (GERD). The investigators hypothesize that the compliance and tolerance to CPAP is affected with the timing of last meal before bedtime and this may also affect the symptoms of GERD.
In a U.S., multicenter, randomized, double-blind, placebo-controlled study, 103 patients were treated for up to eight weeks with placebo, 10 mg, 20 mg, or 40 mg rabeprazole sodium delayed-release tablets once daily. For this and all studies of GERD healing, only patients with GERD symptoms and at least grade 2 esophagitis (modified Hetzel-Dent grading scale) were eligible for entry. Endoscopic healing was defined as grade 0 or 1. Each rabeprazole dose was significantly superior to placebo in producing endoscopic healing after four and eight weeks of treatment. The percentage of patients demonstrating endoscopic healing was as follows:

In addition, there was a statistically significant difference in favor of the rabeprazole sodium 10 mg, 20 mg, and 40 mg doses compared to placebo at Weeks 4 and 8 regarding complete resolution of GERD heartburn frequency (p≤0.026). All rabeprazole sodium groups reported significantly greater rates of complete resolution of GERD daytime heartburn severity compared to placebo at Weeks 4 and 8 (p≤0.036). Mean reductions from baseline in daily antacid dose were statistically significant for all rabeprazole sodium groups when compared to placebo at both Weeks 4 and 8 (p≤0.007).

In a North American multicenter, randomized, double-blind, active-controlled study of 336 patients, the percentage of patients healed at endoscopy after four and eight weeks of treatment was statistically superior in the patients treated with rabeprazole sodium delayed-release tablets compared to ranitidine:

A dose of 20 mg once daily of rabeprazole sodium delayed-release tablets was significantly more effective than ranitidine 150 mg four times daily in the percentage of patients with complete resolution of heartburn at Weeks 4 and 8 (p<0.001). Rabeprazole sodium delayed-release tablets was also more effective in complete resolution of daytime heartburn (p≤0.025), and nighttime heartburn (p≤0.012) at both Weeks 4 and 8, with significant differences by the end of the first week of the study.

The recommended dosage of rabeprazole sodium delayed-release tablets is 20 mg once daily for 4 to 8 weeks.
The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Folic acid groups 1 and 2 receive: 2800 μg FA once a week during the pre-pregnancy period.
BACKGROUND: This study aimed to investigate whether physical activity (PA) is associated with a lower risk of subsequently developing chronic obstructive pulmonary disease (COPD).
METHODS: We conducted this population-based longitudinal follow-up study in a community in Taiwan. This study recruited 61,446 subjects who had participated in the Keelung Community-based Integrated Screening Program (KCIS) between 2005 and 2012. During their participation in KCIS, they were provided with structured questionnaires to collect their baseline characteristics, including weekly PA time. After excluding subjects diagnosed with COPD before they joined KCIS and/or who provided incomplete lifestyle data, 59,457 subjects remained, and were classified into three groups based on their weekly PA time: i.e., as NPA (no regular PA), LPA (low PA, <90 min/week) and HPA (high PA, ≥90 min/week). The primary outcome was a new diagnosis of COPD, followed up until the end of 2015 or their death. Cox proportional-hazard regression was used to assess the impact of PA on the risk of COPD.
RESULTS: The risk of COPD was more than 20% lower in the LPA and HPA groups than in the NPA group. Specifically, the adjusted hazard ratio for the risk of COPD was 0.72 in the LPA group (95% CI, 0.61-0.85, p < 0.001) and 0.79 in the HPA group (95% CI, 0.69-0.90, p < 0.001).
CONCLUSIONS: Our research uncovered an inverse relationship between PA and COPD. The findings suggest that PA might be useful as a strategy for the primary prevention of COPD.
The investigators will conduct a single-center randomized clinical trial at the Jewish General Hospital; an academic tertiary care center in Montreal, Quebec. Researchers will pre-screen stable patients ≥65 years of age admitted to the cardiovascular unit. The investigators will target those that consent and have evidence of frailty or pre-frailty according to the EFT (score ≥1/5). The EFT consists of a chair rise test to screen for physical frailty, a mini-cog test to screen for cognitive impairment, a hemoglobin level and a serum albumin level. Patients will be randomly allocated to the usual-care control group, or the intervention group that will receive targeted treatments depending on the EFT deficits identified. All patients will be outfitted with a hip-worn accelerometer to monitor position, step count, and sleep data during the study period. Patients will undergo a structured questionnaire and physical performance assessment at baseline (upon index admission) and at discharge, and will be contacted by telephone 30 days post-discharge to assess their recovery. The primary endpoint will be represented by the EQ-5D scale (mobility, self-care, mood, pain, and physical activity) measured by blinded observers.
PURPOSE:An anti-inflammatory, antipyretic and anlagesic agent containing a specific theophylline derivative and an acid addition salt thereof, e.g. 7- 3- 4-(3,4- dimethylphenyl)piperazinyl-(1) -n-propyl -theophylline dihydrochloride, as active constituents. CONSTITUTION:An anti-inflammatory, antipyretic and analgesic agent containing a theophylline derivative expressed by formulaI R is H or lower alkyl; Z is formula IV or V (X1, X2, Y1 and Y2 are H, lower alkyl, lower alkoxyl, CF3 or halogen) or pyridyl; X is N or C; n is an integer 2-10  and an acid addition salt thereof as active constituents. The compound expressed by formulaIis administered in a dose of preferably about 3-100mg per day orally or parenterally, e.g. intramuscularly, subcutaneously or intravenously, and used as the above- mentioned drug. The compound expressed by formulaIcan be prepared by reacting a compound expressed by formula II (X is halogen or p-toluenesulfonyloxy) with a compound expressed by formula III.
The application provides coliphage pEC-S163-2.2, and application and preparation thereof. The coliphage (Escherichia coli) pEC-S163-2.2 was deposited at the Guangdong province microbiological bacterial collection center (GDMCC), accession number: the collection number of the building 5 of the Guangzhou city first Zhonglu No. 100 college No. 59 is: GDMCCNo 63107-B1. The application also provides a preparation comprising the coliphage pEC-S163-2.2. The application also provides application of the coliphage pEC-S163-2.2 in preparing a preparation for preventing and treating multi-drug resistant colibacillus infection. The coliphage pEC-S163-2.2 has a good application prospect in preventing, controlling and treating coliform infection.
Obesity is a chronic multi-system disease and major driver of type 2 diabetes and cardiometabolic disease. Nutritional interventions form the cornerstone of obesity and type 2 diabetes management. Some interventions such as Mediterranean diet can reduce incident cardiovascular disease, probably independently of weight loss. Weight loss of 5% or greater can improve many adiposity-related comorbidities. Although this can be achieved with lifestyle intervention, it is often difficult to sustain in the longer term due to adaptive endocrine changes. In recent years glucagon-like-peptide-1 receptor agonists (GLP-1RAs) have emerged as effective treatments for both type 2 diabetes and obesity. Newer GLP-1RAs can achieve average weight loss of 15% or greater and improve cardiometabolic health. There is heterogeneity in the weight loss response to GLP-1RAs, with a substantial number of patients unable to achieve 5% or greater weight. Weight loss, on average, is lower in older adults, male patients and people with type 2 diabetes. Mechanistic studies are needed to understand the aetiology of this variable response. Gastrointestinal side effects leading to medication discontinuation are a concern with GLP-1RA treatment, based on real-world data. With weight loss of 20% or higher with newer GLP-1RAs, nutritional deficiency and sarcopenia are also potential concerns. Lifestyle interventions that may potentially mitigate the side effects of GLP-1RA treatment and enhance weight loss are discussed here. The efficacy of such interventions awaits confirmation with well-designed randomized controlled trials.
To evaluate the efficacy, safety and whether it can reduction of antibiotic use in the treatment of community-acquired pneumonia in children with Anerning granules combined with ceftriaxone sodium.In this study, a randomized, double blind, parallel control of placebo, multi-center clinical study will be established. According to the relevant regulations of the CFDA, 216 cases need to be registered at least.The aim population is children who suffering of community-acquired pneumonia from September 2018 to December 2019. These cases will be devided into treatment group（Anerning particle+ Intravenous ceftriaxone sodium）,control group（Anerning particle simulants+ Intravenous ceftriaxone sodium）. Each group will be treated for 10 days hospitalization and if there is adverse drug reaction during treatment, follow-up until the laboratory indicators are normal. The efficacy indicators of this study were mainly from three dimensions: Frequency of antibiotics at the clinical endpoint, Total disease efficiency, Clinical recovery time. The symptom scores changes of each group before and after treatment were observed.
This study will be conducted within MGH primary care. As with prior work, the investigators will use the hospital's EHR database, the Epic Enterprise Data Warehouse, to identify patients. Patients will be eligible if they are: adults 18-84 years of age with poorly controlled type 2 diabetes (defined as HbA1c \>7.5% for ages 18-69 and \>8.5% for ages 70-84) and a compelling indication for an SGLT-2i or GLP-1RA (including cardiovascular disease, kidney disease, heart failure, or obesity), who are not already prescribed one of these therapies. The investigators will exclude individuals with end stage renal disease, dementia, type I diabetes, or an EHR indicator of hospice care. The investigators will also exclude patients who are not on the MGH diabetes registry, because patients who are excluded from the registry typically have a clinical reason for alternative diabetes goals or care plans. PCPs caring for at least one eligible patient will be included in the trial. Eligible PCPs will be randomized to one of three arms: (1) intervention to address diffusion of responsibility, (2) intervention to address diffusion of responsibility plus additional simplification of the prescribing process, and (3) usual care. Providers randomized to arm 1, the intervention to address diffusion of responsibility will receive an email from a peer offering encouragement and support in prescribing SGLT-2is and GLP-1RAs that includes specific components designed to reduce diffusion of responsibility. The email will also contain a link to clinical and administrative information to support prescribing and an offer for direct support from the peer. Providers randomized to arm 2, the intervention addressing diffusion of responsibility and simplifying the prescribing process will receive the same contact addressing diffusion of responsibility as in arm 1, but they will additionally have access to an experienced administrative team for diabetes medication insurance authorization support. The primary outcome will be the rate of prescriptions for SGLT-2is and GLP-1RAs among eligible patients.
In mNGS-guided treatment group, participants undergo mNGS, using appropriate lower respiratory tract (LRT) specimen, and conventional microbiological diagnostic tests. LRT specimen, such as endotracheal aspiration (ETA), bronchoalveolar lavage fluid (BALF), or protected specimen brush (PSB), will be obtained within 24 hours after the participants entering the ICU. Conventional microbiology diagnostic techniques will be also applied using appropriate LRT specimens and other necessary specimens (such as blood, pleural fluid, urine, et al.). Clinicians alter or confirm the definitive treatment based on mNGS results, as well as results from conventional microbiology diagnostic techniques.
Neuropeptide substance P (SP) belongs to a family of bioactive peptides and regulates many human diseases. This study aims to investigate the role and underlying mechanisms of SP in colitis. Here, activated SP-positive neurons and increased SP expression were observed in dextran sodium sulfate (DSS)-induced colitis lesions in mice. Administration of exogenous SP efficiently ameliorated the clinical symptoms, impaired intestinal barrier function, and inflammatory response. Mechanistically, SP protected mitochondria from damage caused by DSS or TNF-α exposure, preventing mitochondrial DNA (mtDNA) leakage into the cytoplasm, thereby inhibiting the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway. SP can also directly prevent STING phosphorylation through the neurokinin-1 receptor (NK1R), thereby inhibiting the activation of the TBK1-IRF3 signaling pathway. Further studies revealed that SP alleviated the DSS or TNF-α-induced ferroptosis process, which was associated with repressing the cGAS-STING signaling pathway. Notably, we identified that the NK1R inhibition reversed the effects of SP on inflammation and ferroptosis via the cGAS-STING pathway. Collectively, we unveil that SP attenuates inflammation and ferroptosis via suppressing the mtDNA-cGAS-STING or directly acting on the STING pathway, contributing to improving colitis in an NK1R-dependent manner. These findings provide a novel mechanism of SP regulating ulcerative colitis (UC) disease.
Participants will be invited to join three writing activities, lasting 20 minutes daily in D1, D3, and D5 of the same week. For example, to write about a difficult or painful experience related discrimination and their feelings about it.
PURPOSE: A composition containing an ethylacetate extract or a phenol compound of Carthami Flos as a main component is provided. The phenol compound including lignan, flavonoid and serotonin component, derived from the ethylacetate extract of Carthami Flos has excellent effects on improvement of lipid metabolism, and particularly treatment of hyperlipidemia induced from a deficiency in estrogen secretion. CONSTITUTION: Dried Carthami Flos is ground and defatted with hexane, followed by extracting with ethanol or methanol and concentration under reduced pressure. Thereafter, the extract is fractioned with ethyl acetate and concentrated under reduced pressure to give the ethyl acetate extract of Carthami Flos. The ethyl acetate fraction is separated and purified to give a phenol compound. The phenol compound is one of N-feruloyl serotonin, N-(p-coumaroyl)s erotonin, matairesinol, 8'-hydroxyarctigenin, luteolin and acacetin.
The invention belongs to a medicinal preparation, and relates to a nano-scale pediatric diazepam enema and a preparation method thereof. The invention overcomes the defects of the prior art and provides an enema without benzyl alcohol in the prescription and a method for preparing the enema by using a nanotechnology. The prescription of the invention comprises 0.1 percent of diazepam containing main drug, 2.0 percent of propylene glycol, 0.6 percent of ethanol, 0.05 percent of benzoic acid, 0.05 percent of sodium benzoate, 0.1 percent of sodium hydroxide and 97.0 percent of purified water. The preparation method comprises adding propylene glycol, benzyl alcohol and sodium benzoate into purified water, stirring to dissolve to obtain water phase; then stirring the ethanol and the diazepam to dissolve to obtain an oil phase; adding the oil phase into the water phase, stirring for 30min, adjusting the pH value of the solution to 6.2-7.2 with sodium hydroxide or hydrochloric acid, homogenizing the solution for 4-6 times with a high-pressure homogenizer, and filtering with a screen with the diameter of 0.1mm to obtain the final product. The particle size analysis of the product of the invention is less than 100 nm. The product of the invention is used for accurately carrying out rectal administration according to the body weight of the paediatric population at different age stages, and treating febrile convulsion, epilepsy and other diseases.
Twice-daily text messages, 5 days per week, for 24 months. Text message content centered on general health promotion, including getting regular medical checkups and maintaining good dietary and exercise habits.
FIELD: chemical and pharmaceutical industry. SUBSTANCE: liquid wastes of production of allapinine is extracted three times with the help of chloroform, chloroform being separated and washed to neutral reaction. Said wastes are prepared during production of allapinine of aconite rhizome. The process is followed by evaporation. Thus prepared boiled down concentrate or resin wastes of preparing allapinine of above ground part of aconite are treated by 98 ethanol. Thus prepared extract is allowed to stand, supernatant liquid being decanted and filtered. EFFECT: simplifies the method. 5 tbl
Fluid maintenance with 2 ml/kg/h of Ringer's solution of sodium acetate, when SVV\>13%, 4 mL/kg bolus of hydroxyethyl starch will be infused within 5 min. If SVV falls below 13%, the bolus will be suspended. If SVV is still more than 13%, 100 μg of phenylephrine will be administered when CI is more than 2.5 L/min/m2, 1 mg of dopamine will be administered when CI is less than 2.5 L/min/m2. When SVV\<13%, but mean arterial pressure (MAP)\<65 mmHg, 8 μg of norepinephrine will be administered. The hemodynamic status will be repeatedly measured every 10 min.
Of the patients receiving Risedronate Sodium in postmenopausal osteoporosis studies [see Clinical Studies (14)], 47% were between 65 and 75 years of age, and 17% were over 75. The corresponding proportions were 26% and 11% in glucocorticoid-induced osteoporosis trials, and 40% and 26% in Paget’s disease trials. No overall differences in efficacy between geriatric and younger patients were observed in these studies. In the male osteoporosis trial, 28% of patients receiving Risedronate Sodium were between 65 and 75 years of age and 9% were over 75. The lumbar spine BMD response for Risedronate Sodium compared to placebo was 5.6% for subjects less than 65 years and 2.9% for subjects greater than or equal to 65 years. No overall differences in safety between geriatric and younger patients were observed in the Risedronate Sodium trials, but greater sensitivity of some older individuals cannot be ruled out.
Multimodal intravascular imaging technology is used to assess the morphological structure and stability of non-criminal lesions in plaques, categorized into high-risk and non-high-risk groups. High-risk plaques are defined as those that meet any of the following criteria: ① IVUS minimum lumen area \<4.0mm² or OCT minimum lumen area \<3.5mm², ② plaque burden \>70%, ③ presence of thin-cap fibroatheroma, ④ NIRS detects lipid-rich plaques with LRP MaxLCBI4mm \>315, and are considered high-risk if they have at least two of the above four characteristics. A patient is placed in the high-risk group if they have at least one high-risk plaque.